{"id":"vehicle-ophthalmic-solution-qid-to-bid","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This appears to be a formulation study or dose-optimization trial for an ophthalmic therapeutic agent. The notation 'QID to BID' suggests a dose-reduction or frequency-optimization protocol, moving from four times daily dosing to twice daily dosing. Without identification of the active pharmaceutical ingredient, the specific mechanism cannot be determined.","oneSentence":"A vehicle ophthalmic solution formulation designed to be administered topically to the eye at varying frequencies (four times daily reduced to twice daily).","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:40:26.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ophthalmic indication (specific indication not specified in available information)"}]},"trialDetails":[{"nctId":"NCT06424444","phase":"PHASE3","title":"A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2024-04-29","conditions":"Dry Eye Disease","enrollment":421},{"nctId":"NCT07068958","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"ORA, Inc.","startDate":"2025-08-01","conditions":"Dry Eye Disease (DED)","enrollment":200},{"nctId":"NCT03916042","phase":"PHASE2","title":"A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2019-04-23","conditions":"Dry Eye","enrollment":206},{"nctId":"NCT03879863","phase":"PHASE3","title":"The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2019-04-16","conditions":"Dry Eye","enrollment":422},{"nctId":"NCT04250207","phase":"PHASE2","title":"Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2020-06-23","conditions":"Fuchs' Endothelial Corneal Dystrophy","enrollment":65},{"nctId":"NCT05409235","phase":"PHASE2","title":"Nesvategrast (OTT166) in Diabetic Retinopathy (DR)","status":"COMPLETED","sponsor":"OcuTerra Therapeutics, Inc.","startDate":"2022-07-29","conditions":"Diabetic Retinopathy","enrollment":225},{"nctId":"NCT02349516","phase":"PHASE2","title":"Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)","status":"WITHDRAWN","sponsor":"Starr Muscle","startDate":"2015-02","conditions":"Diabetic Retinopathy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vehicle Ophthalmic Solution QID to BID","genericName":"Vehicle Ophthalmic Solution QID to BID","companyName":"Aldeyra Therapeutics, Inc.","companyId":"aldeyra-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A vehicle ophthalmic solution formulation designed to be administered topically to the eye at varying frequencies (four times daily reduced to twice daily). Used for Ophthalmic indication (specific indication not specified in available information).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}